Your browser is old and is not supported. Upgrade for better security.

Invest in Quorum X Diagnostics

The first 4-minute at-home Antigen test for COVID

Pitch Video
Investor Panel


💸 $630K raised in 2020, $100K raised in 2021 thus far ($70K Private, $30K Wefunder)
💥 We went from idea to a Covid product to FDA application in under a year.
🔬Tested 350+ patient samples, results confirmed by 2 independent labs
👩🏻‍⚕️ Team consists of 5 doctors & an Army of interns
💰 3 established Go-To-Market Strategies & National distribution with help of Physician 360.
📌 Anticipated Market Demand of 60-90M tests weekly

Our Team

Global need. We realized we could use the same unique technology (that was used to build our QXD-1 Fast test for Pseudomonal Pneumonia) and use it to build a test for COVID.

The first 4-minute at-home Antigen test for COVID

We are 'testing the waters' to gauge investor interest in an offering under Regulation Crowdfunding. No money or other consideration is being solicited. If sent, it will not be accepted. No offer to buy securities will be accepted. No part of the purchase price will be received until a Form C is filed and only through Wefunder’s platform. Any indication of interest involves no obligation or commitment of any kind. Presently, we are only taking Reservations!  This means right now no monies will be taken, however; you can reserve your investment now.  It is only when we hit 50K raised and file our schedule C paperwork and go live.  At that point Wefunder will send you an update and ask you if you are still interested in investing and to confirm your investment amount.  It will only draw funds if you confirm your investment at that time.


  • The 4-minute COVIDNOW® antigen test currently has the fastest development time compared to competitive products that currently have EUA approval.
  • COVIDNOW® is SIMPLE. It was designed to be easy to make self-testing at-home a viable option for everyone!
  • QXD’s COVIDNOW® test is an antigen test vs. an antibody test meaning it can detect active infection.
  • The sensitivity of the COVIDNOW® test is able to detect an active infection in asymptomatic individuals.
  • COVIDNOW® does not require a prescription.
  • The COVIDNOW® APP uses the latest in A.I. technology making it possible to analyze the test cassette result much sharper than that of the naked eye. 
  • The sample from the COVIDNOW® test does not have to be sent off to a lab; it is not a collection kit.
  • QXD has partnered with Physician 360, a telemedicine service, to provide immediate connectivity to a board-certified physician for a consultation.
  • The QXD COVIDNOW® at-home test kit has a mobile phone APP that using AI technology and works in conjunction with the telemedicine service.
  • QXD's partnership with Physician 360, the telemedicine service, provides an additional distribution channel through P360 kiosks located in 1,000+ stores across all 50 states.
  • All patent applications required for the proprietary technology used to produce QXD’s rapid diagnostic tests have been submitted and are currently pending.
  • QXD has a clear exit strategy. Within five years continue the development of the proprietary technology and build out the scientific and organizational infrastructure of the business model at which point it would be optimal for a larger corporation to take the vision to the next level.
  •  COVIDNOW® is pending EUA approval

Making an investment is a huge decision and one that we don’t take lightly. Rest assured, we are dedicated, determined, and passionate about what we are doing.

QXD has an amazing team and we're the team to get it DONE!